TargetBeta
PARP1
poly(ADP-ribose) polymerase 1 · also PARP, ARTD1, Poly-PARP, PARS · Zinc fingers PARP-type
10 programs in company-led studies act on PARP1, from 8 companies: 1 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (8 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| olaparibrule | AstraZeneca | phase 4 | 7823 running | PARP2, PARP3 | ChEMBL |
| niraparibrule | GlaxoSmithKline | phase 4 | 4310 running | PARP2 | ChEMBL |
| saruparibrule | AstraZeneca | phase 3 | 1411 running | PARP2 | the studies' text |
| nesuparibrule | Jeil Pharmaceutical | phase 2 | 43 running | PARP2, TANK, TNKS | NCIt |
| palacaparib | AstraZeneca | phase 2 | 33 running | – | a judged reading |
| senaparibrule | Impact Therapeutics | phase 2 | 120 running | PARP2 | ChEMBL |
| PARP1 Inhibitor HS-10502rule | Hansoh Pharmaceutical Group | phase 1 | 22 running | – | the studies' text |
| DM5167rule | DIGMBIO | phase 1 | 11 running | – | the studies' text |
| HSK46256rule | Haisco Pharmaceutical Group | phase 1 | 11 running | – | the studies' text |
| TQB3122 | Sino Biopharmaceutical | phase 1 | 11 running | – | the company's pipeline |
Conditions their studies are in
- Breast Neoplasms, 6 programs
- Ovarian Neoplasms, 6 programs
- Prostatic Neoplasms, 4 programs
- Neoplasms, 3 programs
- Carcinoma, Non-Small-Cell Lung, 1 program
- Neoplasm Metastasis, 1 program
- Prostatic Neoplasms, Castration-Resistant, 1 program
- Small Cell Lung Carcinoma, 1 program
- Stomach Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 26, 2026niraparib · GlaxoSmithKline · phase 4 · NCT03981796
- Dec 2026TQB3122 · Sino Biopharmaceutical · phase 1 · NCT07269145
- Dec 31, 2026saruparib · AstraZeneca · phase 3 · NCT06713369
- Mar 2027olaparib · AstraZeneca · phase 4 · NCT07371104
- Sep 29, 2027palacaparib · AstraZeneca · phase 2 · NCT05123482
- Dec 30, 2028HSK46256 · Haisco Pharmaceutical Group · phase 1 · NCT07695142
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.